This course delivers a focused breakdown of the FDA’s direct final rule that replaces outdated terminology in human drug and biological product regulations. Learn exactly how to update your regulatory submissions and internal documentation by adopting ‘nonclinical’ instead of ‘animal’, ‘preclinical’, or ‘in vitro’ in all relevant contexts. Master the new definitions as they apply to IND, NDA, BLA, and postmarketing materials. Ensure your organization is prepared for the compliance deadline and avoids costly regulatory delays.
In this course you will learn the following:
* Identify the key terminology changes and their regulatory context.
* Understand the expanded definition of “nonclinical test” and “nonclinical study.”
* Apply the new terminology in regulatory submissions and communications.
* Recognize the impact of these changes on compliance and reporting.
* Understand the consequences of non-compliance with the updated regulations.
